- Home
- ZTEK vs LUNG Comparison
ZTEK vs LUNG Comparison
Compare ZTEK & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | LUNG |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 72.2M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | LUNG |
|---|---|---|
| Price | $0.63 | $1.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 133.4K | ★ 645.4K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,789,000.00 |
| Revenue This Year | N/A | $6.20 |
| Revenue Next Year | N/A | $21.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $0.54 | $1.31 |
| 52 Week High | $1.84 | $8.10 |
Technical Indicators
Market Signals| Indicator | ZTEK | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 55.71 |
| Support Level | $0.55 | $1.44 |
| Resistance Level | $0.75 | $1.93 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 69.90 | 50.00 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.